Tradestie Institutional Equity Comparison Engine
AYTU vs IBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AYTU Overall Edge
AYTU Captures Institutional Edge (2โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AYTU BioPharma, Inc. Common Stock (AYTU) driven by superior Valuation, Momentum & Technical while IBIO counters with relative strength in Growth & Margin. Fundamentally, AYTU trades at 9.2x Forward P/E with -14.4% operating margin (+6.4% YoY revenue) versus IBIO at N/M Forward P/E and -3025.6% operating margin (+975.0% YoY). In options structure, AYTU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
AYTU
AYTU 9.2x vs IBIO N/M Fwd P/E
Growth & Margin Winner
IBIO
Op Margin -14.4% vs -3025.6% ยท YoY +6.4% vs +975.0%
Momentum & Technical Winner
AYTU
1Y -12.1% vs -37.7% ยท 52W Pos 5% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
AYTU
NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap
$19.6M
1M Return
-11.27%
1Y Return
-12.14%
Forward P/E
9.2x
Unified AI Score
48.9 / 100
HOLD
Tech 49.0
Fund 53.0
Flow 50.0
Mom 64.0
IBIO
NASDAQ
iBio, Inc. Common Stock
Pharmaceutical Preparations
$0.72
-2.04% 1D
Market Cap
$53.7M
1M Return
-6.46%
1Y Return
-37.67%
Forward P/E
N/M
Unified AI Score
46.0 / 100
HOLD
Tech 45.0
Fund 46.0
Flow 50.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AYTU -12.14%
IBIO -37.67%
Spread: +25.53 pp (AYTU Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AYTU Revenue | IBIO Revenue | AYTU Op. Margin | IBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | $0M | -230.1% | -782.4% | AYTU |
| FY2020 | $30M | $0M | -76.5% | -854.9% | AYTU |
| FY2021 | $70M | $0M | -89.7% | -1312.1% | AYTU |
| FY2022 | $100M | $0M | -113.7% | -1576.3% | AYTU |
| FY2023 | $110M | N/A | -15.9% | N/A | AYTU |
| FY2024 | $70M | $0M | -2.4% | -7392.9% | AYTU |
| FY2025 | $70M | $0M | -11.8% | -4650.5% | AYTU |
| FY2026 | $60M | $0M | -14.4% | -35141.0% | AYTU |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AYTU | IBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $19.6M | $53.7M | Larger Scale | IBIO |
| Trailing P/E Ratio Valuation | 9.2x | N/M | Lower Multiple | AYTU |
| Forward P/E Ratio Valuation | 9.2x | N/M | Lower Multiple | AYTU |
| Revenue Growth (YoY) Growth | +6.4% | +975.0% | Higher Growth | IBIO |
| Operating Margin (TTM) Profitability | -14.4% | -3025.6% | Higher Margin | AYTU |
| Net Profit Margin Profitability | -24.8% | 0.0% | Higher Margin | IBIO |
| Return on Equity (ROE) Capital Efficiency | -52.5% | -51.8% | Higher ROE | IBIO |
| 52-Week Range Position Momentum | 5% ($2โ$3) | 1% ($1โ$4) | Stronger Trend | AYTU |
| Beta / 30D Volatility Risk Regime | 0.65ฮฒ ยท 35% Vol | 2.07ฮฒ ยท 89% Vol | Lower Realized Risk | AYTU |
| Unified Institutional Score Composite Signal | 48.9 / 100 (HOLD) | 46.0 / 100 (HOLD) | Higher Composite | AYTU |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AYTU vs IBIO Buy Guide
AYTU
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AYTU nor IBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.